Methods and compositions for treating pulmonary hypertension
a pulmonary hypertension and composition technology, applied in the direction of drug compositions, cardiovascular disorders, dispersed delivery, etc., can solve the problems of pulmonary hypertension, inexorable disease progress, and quite often sudden death, so as to maximize the effect of treating pulmonary hypertension
Inactive Publication Date: 2018-11-15
UNITED THERAPEUTICS CORP
View PDF0 Cites 1 Cited by
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Benefits of technology
The present patent text describes methods for treating conditions associated with elevated blood pressure by increasing nitric oxide (NO) production in the body. This can be accomplished by co-administering a NO-releasing compound and a PDE5 inhibitor to prevent premature breakdown of the NO-releasing compound. The NO-releasing compound can be administered through inhalation, resulting in aerosol particles that can be deposited in the lung for maximum efficacy in treating pulmonary hypertension. The aerosol exhibits specific properties, including a mass median aerodynamic diameter and geometric standard deviation, to ensure proper delivery and effectiveness. The technical effects of this patent include decreasing blood pressure, increasing blood flow to tissue, and inducing vasodilation.
Problems solved by technology
In addition, certain infectious diseases, such as HIV and liver diseases with portal hypertension may cause pulmonary hypertension.
Generally, however, disease progress is inexorable via syncope and right heart failure and death is quite often sudden.
Fluid buildup in the lung (pulmonary edema) can result, with an associated decrease in lung function that can in some cases be fatal.
Pulmonary hypertension may also ultimately result in a potentially fatal heart condition known as “cor pulmonale,” or pulmonary heart disease.
Method used
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View moreExamples
Experimental program
Comparison scheme
Effect test
Embodiment Construction
[0015]Unless otherwise specified, “a” or “an” means “one or more.” In one aspect, provided herein are methods for treating a subject suffering from a condition associated with an elevated blood pressure. The term “subject” as used herein refers to living multi-cellular organisms, including vertebrate organisms, a category that include both human and non-human mammals. The methods and compositions as disclosed herein have equal application in medical and veterinary settings. Thus, the general term “subject” under the treatment is understood to include all animals, such as humans, domestic animals, wild animals and laboratory animals.
[0016]The term “treating” or “treatment” covers the treatment of a disease or disorder described herein, in a subject, such as a human, and includes: (i) inhibiting a disease or disorder, e.g., arresting its development; (ii) relieving a disease or disorder, e.g., causing regression of the disorder; (iii) slowing progression of the disorder; and / or (iv) i...
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More PUM
| Property | Measurement | Unit |
|---|---|---|
| mass median aerodynamic diameter | aaaaa | aaaaa |
| diameter | aaaaa | aaaaa |
| diameter | aaaaa | aaaaa |
Login to View More
Abstract
The present disclosure provides compositions and methods for treating pulmonary hypertension. The compositions and methods are based on administering a NO-releasing compound, such as nitrite, to a subject in need thereof in an amount sufficient to increase the level of circulating nitric oxide (NO), a potent vasodilator, thereby reducing the subject's blood pressure and increasing blood flow.
Description
CROSS-REFERENCE TO RELATED APPLICATIONS[0001]This application claims the benefit of and priority to U.S. Provisional Appl. No. 62 / 444,547, filed Jan. 10, 2017, the disclosure of which is incorporated by reference herein in its entirety.TECHNICAL FIELD[0002]The present invention relates to compositions and methods for treating pulmonary hypertension based on administering to a subject in need thereof a nitric oxide (NO)-releasing compound and a phosphodiesterase type-5 (PDE5) inhibitor.BACKGROUND[0003]All blood is driven through the lungs via the pulmonary circulation in order, among other things, to replenish the oxygen which it dispenses in its passage around the rest of the body via the systemic circulation. The flow through both circulations is in normal circumstances equal, but the resistance offered to it in the pulmonary circulation is generally much less than that of the systemic circulation. When the resistance to pulmonary blood flow increases, the pressure in the circulati...
Claims
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More Application Information
Patent Timeline
Login to View More Patent Type & Authority Applications(United States)
IPC IPC(8): A61K31/53A61K9/00A61P9/12
CPCA61K31/53A61K9/0075A61K9/0078A61P9/12A61K2300/00A61K33/00A61K45/06A61K9/008
Inventor ROTHBLATT, MARTINE A.
Owner UNITED THERAPEUTICS CORP